GLP-1 receptor raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2025-09-21 and is reviewed periodically as new material appears.
Clinical development of this compound followed earlier short-acting GLP-1 analogues that required frequent injection. Once-weekly subcutaneous formulations entered use after 2017, and an oral formulation using a permeation enhancer later became available. The oral version pairs the peptide with sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, a carrier that improves uptake across the gastric epithelium. Interest has expanded from glycaemic control into weight management and metabolic liver disease. Regulatory status and approved indications differ between countries, and the product remains subject to ongoing safety monitoring.
Semaglutide is a synthetic peptide that acts as an agonist at the glucagon-like peptide-1 receptor. It is a structural analogue of human GLP-1(7-37), modified to resist enzymatic degradation by dipeptidyl peptidase-4. The peptide backbone contains alpha-aminoisobutyric acid at position 8, a substitution that stabilises the helix and slows cleavage. A fatty diacid side chain attached through a linker at lysine 34 promotes binding to serum albumin, which extends the circulating half-life. These two modifications together allow less frequent administration than native GLP-1 requires.
Activation of the GLP-1 receptor couples to Gs signalling and raises intracellular cyclic AMP in pancreatic beta cells. The resulting insulin release depends on prevailing glucose concentrations, so the effect is greater when glucose is elevated. Receptor engagement also suppresses glucagon secretion and slows gastric emptying, which flattens post-meal glucose excursions. In the central nervous system, signalling in hypothalamic and brainstem regions is associated with reduced appetite and lower energy intake. Studies continue to examine effects on cardiac, renal and hepatic endpoints; whether those benefits are independent of weight change remains an open question.
Identity and purity are assessed with reversed-phase high-performance liquid chromatography, which separates the peptide from related impurities by hydrophobicity. Mass spectrometry confirms molecular weight and detects truncation or modification products. Peptide mapping after enzymatic digestion verifies the amino acid sequence. Quantitation is often performed by LC-MS/MS or by immunoassay, and the two approaches can give different values because they measure different things. Method validation parameters such as accuracy, precision, and limit of quantitation are reported alongside results.
Certificate of analysis documents from suppliers typically report purity by chromatographic area, water content, and counter-ion identity. Independent verification is advisable because reported values can be generated under differing conditions. Impurity profiles matter for research use, where aggregates, deamidation products, and residual solvents may influence experimental results. Container, lot, and chain-of-custody records support traceability. Analytical results are method-dependent, so comparisons between laboratories require the same procedure and reference standards.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C187H291N45O59 | Parent peptide; salt forms also reported |
| Molecular mass | about 4113.6 Da | Average mass of the free peptide |
| Peptide length | 31 amino acids | Backbone related to GLP-1(7-37) |
| Key substitution | Aib at position 8 | Blocks DPP-4 cleavage |
| Albumin binding | Via C-18 diacid side chain | Prolongs circulation time |
Semaglutide is a synthetic peptide analogue of glucagon-like peptide-1, a gut hormone released after nutrient intake. The molecule contains 31 amino acid residues and differs from the native sequence at several positions. A non-natural residue at position eight resists the enzyme that normally truncates the hormone, while a lysine-linked fatty diacid side chain promotes binding to serum albumin. These two modifications extend the circulating half-life from minutes to roughly one week. The peptide is produced by solid-phase synthesis followed by selective acylation, and its identity and purity are confirmed by spectrometric and chromatographic techniques.
The primary target is the GLP-1 receptor, a class B G protein-coupled receptor expressed on pancreatic beta cells, in the gut, and in several brain regions. Receptor activation raises intracellular cyclic AMP, which potentiates glucose-dependent insulin secretion and lowers glucagon release when blood glucose is elevated. Signalling in the hypothalamus and brainstem is associated with reduced appetite and slower gastric emptying. Because the insulinotropic effect depends on prevailing glucose levels, the hypoglycaemic risk of the peptide alone is described as low in most study settings. The relative contribution of peripheral and central actions remains an active research question.
Receptor activation occurs at GLP-1 receptors distributed across pancreatic islets, the hypothalamus, and the gastrointestinal tract. Binding triggers G protein signaling that raises cyclic AMP and enhances glucose-dependent insulin release. Because the effect depends on prevailing glucose levels, insulin secretion does not rise when blood sugar is already low. Signaling in the brain and gut also influences appetite and gastric emptying, which is why the compound appears in both metabolic and weight-related research literature.
Development began in the early 2010s with the goal of extending GLP-1 activity beyond the brief window achieved by native peptide infusion. The earliest approved formulation was a subcutaneous injection given once weekly. A later oral tablet pairs the peptide with an absorption enhancer, sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, usually shortened to SNAC. That carrier lowers local pH and helps the peptide cross gastric tissue. Both routes deliver the same active molecule.
Semaglutide is a synthetic peptide analog of human glucagon-like peptide-1, a gut hormone released after meals. Its backbone retains the GLP-1 sequence but incorporates two substitutions that slow enzymatic breakdown by dipeptidyl peptidase-4. A short polyethylene glycol linker and a C18 fatty diacid are attached to the peptide chain, allowing the molecule to bind serum albumin and remain in circulation far longer than the native hormone. The result is a circulating half-life measured in days rather than the minutes typical of endogenous GLP-1.
IgA vasculitis (Henoch-Schönlein purpura) Acute hemorrhagic edema of infancy Urticarial vasculitis Cryoglobulinemic vasculitis Erythema elevatum diutinum Granuloma faciale ANCA-associated vasculitis Arthropod bites Platelet dysfunction or deficiency Cholesterol emboli Septic emboli Livedoid vasculopathy
Professor Juan J. Calvete is a researcher in venomics at the biomedical institute in Valencia and has extensively explained the process involved in untangling and analysing venom (Once in 2007 and recently in 2017.) These involve the following steps: (1) Venom collection, (2) Separation and quantification, (3) Identification and (4) Representation of components found.
The term "Sudetenland" can already be found in geographical literature as early as 1866. In the 19th century, however, the term referred only to the mountain range from the Zittau Basin to the Moravian Gate. In 1902, the publicist and politician Franz Jesser used the term for the first time as a pars pro toto, applying "Sudetenland" to all areas of Bohemia, Moravia, and Austrian Silesia that were then inhabited by a majority of German speakers. Initially, the reception of this newly coined term was slow. In the 1920s, after the territories had become part of Czechoslovakia, publishers, journals, book series, as well as political, popular science, and regional-cultural publications began to adopt it. It eventually also came into circulation as a designation in historical and ethnographic periodicals and monographs. The popularity of the term continued to rise in the 1930, especially after the founding of the Sudetendeutsche Heimatfront in 1933 and later the Sudeten German Party in 1935. In the wake of growing nationalism, the name "Sudetendeutsche" (Sudeten Germans) emerged by the early 20th century. It originally constituted part of a larger classification of three groupings of Germans within the Austro-Hungarian Empire, which also included "Alpine Deutschen" (Alpine Germans) in what later became the Republic of Austria and "Balkandeutsche" (Balkan Germans) in Hungary and the regions east of it. Of these three terms, only the term "Sudetendeutsche" survived, because of the ethnic and cultural conflicts within Bohemia.
March 2, 1982: Decree on the Interministerial Committee for Women's Rights. March 8, 1982: First national Women's Day in France; announcement of several upcoming measures on women's rights (abortion reimbursed at 100%, women's quotas in municipal and regional elections — ruled unconstitutional in 1982 —, system for recovering unpaid alimony, proposed laws against sexism and for gender equality in employment, new status of "co-farmer," and disappearance of the "head of household" notion); the Legion of Honor includes a special class of working women. April 1982: The law on the general status of civil servants enshrines the principle of equal access to public employment. May 7, 1982: Law amending Article 7 of Ordinance 59-244 of February 4, 1959, on the general status of civil servants and containing various provisions on the principle of equal access to public employment. July 10, 1982: Law on the spouses of artisans and shopkeepers working in the family business. August 4, 1982: Law repealing Article 331 (paragraph 2) of the Penal Code; as a result, indecent or unnatural acts with a minor of the same sex (homosexuality) are no longer punishable by correctional penalties. December 29, 1982: Finance law for 1983. It includes the removal of the "head of household" concept from the General Tax Code. December 31, 1982: The cost of abortion is covered by health insurance and the State. July 1, 1983: Law authorizing the ratification of a Convention on the Elimination of All Forms of Discrimination Against Women, opened for signature in New York on March 1, 1980.
Sources: en.wikipedia.org
== Clinical Significance == Diseases affecting the carnitine shuttle include carnitine palmitoyltransferase I deficiency, carnitine palmitoyltransferase II deficiency, and carnitine-acylcarnitine translocase deficiency, among others. A common symptom among them includes fatigue that presents as an intolerance to physical exertion, with symptoms varying wildly between the main three. Treatment usually consists of dietary supplements, avoidance of fasting and prolonged exercise, and treatment of complications, such as myoglobinuria, hypoglycemia, and hepatic dysfunction. CPT1A has also been investigated as a therapeutic target in cancer. In prostate cancer models, inhibition of CPT1A by the cisplatin prodrug Platin-L suppressed fatty-acid oxidation and increased cellular dependence on glucose.
== Description == There is no mention of the Korean People's Revolutionary Army in documents written by Kim Il Sung himself during his time in the Soviet Army. Coined in the wake of the May 25th Instructions, the purported army is connected to Kim Il Sung's cult of personality initiated by the guerrilla faction from the Soviet Army's 88th Separate Rifle Brigade, which seized power in North Korea. The KPRA was first mentioned in the late 1940s. Korean People's Revolutionary Army was allegedly founded on 25 April 1932. North Korean historiography credits the defeat of Japan in 1945 mostly to the KPRA, downplaying Soviet involvement. From 1978, North Korea marked 25 April as the "true" founding date of the Korean People's Army (KPA), with the KPA being claimed to just be the reconstitution of the KPRA. North Korean leader Kim Jong Un moved back the KPA's official founding date back to its original date of 8 February 1948, with 25 April instead becoming the official foundation date of the KPRA
=== Growstones === Growstones, made from glass waste, have both more air and water retention space than perlite and peat. This aggregate holds more water than parboiled rice hulls. Growstones by volume consist of 0.5 to 5% calcium carbonate – for a standard 5.1 kg bag of Growstones that corresponds to 25.8 to 258 grams of calcium carbonate. The remainder is soda-lime glass.
Sources: en.wikipedia.org
It belongs to the incretin mimetic class and acts as a long-acting glucagon-like peptide-1 receptor agonist. The class includes several peptides with different half-lives and routes of administration.
The side chain enables reversible binding to albumin in the bloodstream, which protects the peptide from rapid renal clearance. This extends the interval between administrations compared with unmodified GLP-1.
No. It shares much of the native sequence but carries substitutions and an added side chain. These changes increase stability against enzymatic breakdown.
The lyophilized powder is dissolved in a suitable solvent, often sterile water or a buffered diluent, with gentle mixing rather than vigorous shaking. Foaming and shear should be avoided because they can promote aggregation. The resulting solution is then stored cold and protected from light.